Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Does anyone know

It's not pure conjecture. It's pretty clear from the statement PTSC included that under the new agreement, Alliacense would expect to receive $300K of the $1.5M fee that was paid in the 2nd quarter of FY13. That's 20%. The previous agreement had TPL getting 15%.

"In February 2013, PDS received a license fee installment attributable to the January 2013 satisfaction of a contingency contained in an MMP license agreement entered into in May 2012. Alliacense has asserted a claim against PDS for $300,000 under the premise that it is owed a percentage of the license fee installment pursuant to the Program Agreement it entered into with PDS, TPL and us in July 2012"

Share
New Message
Please login to post a reply